News and Events, Recent News

BriaCell Presenting at Upcoming Cancer Conference

– Further Investigation on Mechanism of Action of its Lead Drug Candidate, Bria-IMT™, at AACR event – BERKELEY, Calif. and VANCOUVER, British Columbia, February 5, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will present a poster on the mechanism of action […]

News and Events, Recent News

BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT™

BERKELEY, Calif. and VANCOUVER, British Columbia, January 31, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, provides an update on its operations. Recent Corporate Milestones Recent Clinical Update: BriaCell is pleased to provide a further update on its ongoing clinical trial of […]

Recent News

BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, January 3, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is providing a clinical update regarding its ongoing clinical trials of Bria-IMT™ (formerly referred to as SV-BR-1-GM). BriaCell currently is enrolling patients in two separate but […]

News and Events, Recent News

BriaCell To Attend Biotech Showcase™ 2018

BERKELEY, Calif. and VANCOUVER, British Columbia, January 2, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending Biotech Showcase™ 2018. The conference will be held January 8-10, 2018 at Hilton San Francisco Union Square (333 O’Farrell St, […]

News and Events, Recent News

BriaCell Announces Closing of Warrant Incentive Program

Berkeley, CA and Vancouver, BC – December 21, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company“) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce it has closed the warrant incentive program (the “Warrant Incentive Program“) announced on October 13, 2017, intended to encourage the exercise of outstanding common share purchase warrants of the Company. […]

News and Events, Recent News

Dr. Bill Williams Guest Appearance at “CEO Money” Radio Show

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that Dr. Bill Williams, BriaCell’s President & CEO, will appear as a guest on the radio show “CEO MONEY.” CEO MONEY, […]

News and Events, Recent News

BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance

BERKELEY, Calif. and VANCOUVER, British Columbia, November 13, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today disclosed the allowance by the US Patent and Trademark Office (USPTO) and also the European Patent Office (EPO) of two patent […]

News and Events, Recent News

BriaCell Provides Clinical Update

BERKELEY, Calif. and VANCOUVER, British Columbia, November 6, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today released a clinical update on its ongoing Phase I/IIa study of its lead vaccine candidate, BriaVax™, in advanced breast cancer patients. […]

News and Events, Recent News

FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to their Immunotherapy in Patients with Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Oct 30, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, announced today that the FDA has approved the roll-over combination study of BriaVax™ with pembrolizumab {Keytruda; manufactured by Merck & Co., Inc. (NYSE: MRK)} […]

Recent News

BriaCell Announces Warrant Incentive Program

Berkeley, CA and Vancouver, BC – October 13, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company“) (TSXV: BCT) (OTCQB: BCTXF) announced today that it is introducing a warrant exercise incentive program (the “Incentive Program“) designed to encourage the early exercise of up to approximately 26 million outstanding common share purchase warrants (the “Warrants “). […]